JAB-22000 / Jacobio Pharma - LARVOL DELTA

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83% (PRNewswire) - "...There are seven preclinical programs of Jacobio that are all new targets and are expected to submit IND applications as one of the first three globally. These include JAB-24114 (an undisclosed target in tumor metabolic pathway), JAB-BX300 (an undisclosed target in the RAS pathway), which is scheduled to submit an IND application in 2022, and JAB-26766...to submit an IND application during 2022 to 2023...JAB-23400 (KRASmulti inhibitor), JAB-22000 (KRAS G12D inhibitor), JAB-23000 (KRAS G12V inhibitor), JAB-30000 (P53 inhibitor) will submit IND applications during 2023 to 2024...Jacobio will submit a registrational clinical trial application for KRAS G12C inhibitor (JAB-21822) in China in 2022 and is expected to submit a New Drug Application (NDA) during 2023 to 2024..."

IND • New trial • Non-US regulatory • Oncology